Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-05-15

FDA Approved: TRELEGY ELLIPTA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) from GlaxoSmithKline LLC, with changes to the prod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Snippet

SUPPL AP for TRELEGY ELLIPTA (FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE)